GRMN vs LCTX · P/E 28, rev $6.30B vs rev $9.5M
Garmin Ltd (GRMN) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Garmin Ltd (GRMN) is a scientific & technical instruments company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported GRMN revenue for 2024-12-28 was $6.30B. Net income was $1.41B. Revenue was up 20.4% from 2023-12-30 to 2024-12-28. GRMN currently screens at market cap $41.35B and trailing P/E 28.3.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
GRMN currently screens at market cap $41.35B and trailing P/E 28.3. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the GRMN and LCTX stock pages for the full models.
Not investment advice.